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Opinion statement
Irritability is a common neuropsychiatric feature of Huntington’s disease (HD), with
prevalences varying from 38% to 73%. Similar prevalences of irritability are reported
in other neurodegenerative disorders and traumatic brain injury, especially when the
frontal lobe is involved. Before therapeutic interventions are initiated, the clinician
should analyze the severity and frequency of the irritable behavior. By examining
irritability in a broader spectrum, a tailor-made treatment can be provided.
In general, I recommend as a first step a selective serotonin reuptake inhibitor
(SSRI), such as sertraline, or the mood stabilizer valproate; they both have a mild
side effect profile. Next, if the result is insufficient, I advise a switch between
these two medications. As an alternative, I recommend a switch to a low dose
of an atypical antipsychotic, preferably twice daily. Buspirone may be another
alternative. Both antipsychotics and busp i r o n ea r ea l s ou s e da sa na d d - o n .O t h e r
mood stabilizers and beta-adrenergic receptor antagonists should only be used
when earlier treatments are ineffective. The use of acetylcholinesterase inhibitors
for the treatment of irritability is discouraged, as results are unclear. Synthetic
cannabinoids are an interesting new therapeutic option, though their “illicit”
c o m p o u n da n ds i d ee f f e c tp r o f i l em a k et h e mn o taf i r s t - l i n eo p t i o n .
Itisimportanttoidentifypossiblecomorbidpsychiatricdisorders,becauseirritabilitymay
be secondary to a psychiatric condition, and the choice of medication partly depends on
theco-occurrenceofaspecificpsychiatricdisorder.Forexample,antipsychoticmedication
would be the treatment of choice in delusional HD patients with excessive irritability,
i n s t e a do fa nS S R Io rv a l p r o a t e .
Besides psychiatric comorbidity, the choice of medication also depends on the general
medical condition, the side effect profile, and drug-drug interactions with other
medications in concomitant use. Patients with advanced disease are particularly
likely to be using various other types of medications.
In addition to pharmacotherapy, behavioral therapy or other psychotherapeutic
interventions may be helpful to reduce levels of stress and should be considered.Introduction
Huntington’s disease (HD) is a progressive neurodegen-
erative disorder characterized by motor symptoms, cog-
nitivedecline,andpsychiatricdisorders[1].HDiscaused
bya trinucleotideexpansion in the IT15 gene,codingfor
the mutant protein huntingtin, and has an autosomal
dominant hereditary pattern. Neurodegeneration occurs
primarily in the striatum and cerebral cortex. The onset
of HD most commonly occurs between 30 and 50 years
of age, and the average disease duration is 16 years.
Althoughmotorsymptomsremainattheforefrontof
the clinical diagnosis, neuropsychiatric symptoms often
precede the onset of motor symptoms. Next to depres-
sion, obsessive-compulsive disorder, and anxiety, irrita-
bility and aggression are frequent neuropsychiatric
symptomsinHD[2,3,4].Irritablepatientsarefrequently
hardtogetalongwith,haveemotionallabilityanderup-
tions, and demonstrate outbursts in response to minor
provocations.Theburdenofthisneuropsychiatricsymp-
tom is highly associated with functional disability.
The term irritability is often poorly defined and is
used as synonym for agitation, hostility, aggressive
behavior, and violent outbursts. Irritability is best
defined as a temporary mood state characterized
by impatience, intolerance, and reduced control over
temper, which usually results in verbal or behavioral
outbursts. It includes elements of anger, aggression, and
reducedimpulsecontrolandcanoccurindependentlyof
other neuropsychiatric conditions [5,6].
A variety of psychotropic medications are used to
treat irritability in HD, although no medication is of-
ficially approved for this indication. In this review of
the literature, we aimed to investigate all reported
treatments for irritability in HD.
The present level of evidence is based on small
studies, with different definitions of irritability and
measurement tools, and many patients used concom-
itant medications that may have affected the clinical
outcome. In addition to these methodologic short-
comings, the choice of the medications in the studies
examined seems to be rather arbitrary. For example,
only one publication is available on the use of a selec-
tive serotonin reuptake inhibitor (SSRI) [7, Class IV],
whereas in clinical practice, SSRIs are often prescribed
as a first-choice treatment for irritability.
Most of the studies discuss the use of antipsychotics,
in particular olanzapine [8,9,10,11, Class IV]. Relatively
largecaseseriesshowanimprovementofirritabilityafter
initiating treatment with olanzapine, indicating that
olanzapine may be an effective treatment for irritability.
However,olanzapinehasnotbeencomparedwithother
medications, so the results are inconclusive.
So far, only one study comparing the effect of
two different medications (lithium carbonate and
haloperidol, in a crossover study), and their combi-
nation, has been published [12, Class III]. Recently,
a placebo-controlled study measuring the effect
of nabilone was published, showing an overall
improvement in behavior [13￿, Class III].
In conclusion, there is a low level of evidence for
current treatments of irritability, and systematic research
with randomized controlled trials is warranted to
measure the effect of medication.
Treatment
Pharmacologic treatment
Selective serotonin reuptake inhibitors (SSRIs)
Sertraline
A hospitalized patient showed a “dramatic improvement” in irritability
shortly after starting sertraline (100 mg), in combination with an
ongoing treatment of haloperidol, whereas earlier treatment with
carbamazepine was not effective [7, Class IV]. Another patient improved
withsertraline aftertreatments withseveralother psychotropic medications
had been ineffective [7, Class IV].
Contraindications No strict contraindications.
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inhibitors or with the antipsychotic drug pimozide. Sertraline may displace
warfarin from plasma proteins and increase the prothrombin time. Because
sertraline is metabolized by the hepatic CYP2D6 enzyme, sertraline may
interfere with the metabolism of other drugs that are metabolized by
CYP2D6, especially in so-called poor metabolizers [14].
Main side effects Most adverse effects appear within the first 1 to 2 weeks, and they generally
subside or resolve spontaneously. Sexual dysfunction, gastrointestinal
problems (nausea, diarrhea, anorexia, vomiting, and dyspepsia), weight gain
or loss, and headache are common adverse effects of SSRIs. Less frequent
adverse effects are anxiety, suicidal tendencies, insomnia, sedation, and vivid
dreams or nightmares.
Special points SSRIs require several weeks to produce a beneficial effect on behavioral
problems, whereas a fast response is usually needed. SSRIs may be especially
effective for irritability associated with depression.
Azapirones
Buspirone
Episodic aggression that was due to a subjective sense of anger and
irritability in a patient with juvenile-onset HD was effectively treated
with 60 mg of buspirone per day [15, Class IV]. Agitation and aggressive
behavioralsoabatedina74-year-oldpatienttreatedwithbuspirone(10mg
three times per day) [16, Class IV]. Dramatic responses on buspirone
at a dosage of 20 mg daily were described after initial treatments with
haloperidol and carbamazepine [17,C l a s sI V ] .
Contraindications Buspirone should be used with caution by persons with hepatic or renal
impairment.
Main drug interactions If buspirone is used in combination with serotonergic agents, there is an
increased risk for the occurrence of a serotonin syndrome. Buspirone may
increase the plasma concentration of haloperidol [14]. Agents with an
inhibitory effect on CYP3A4 (eg, diltiazem, verapamil, itraconazole,
erythromycin) increase the buspirone plasma concentration.
Main side effects The most common adverse effects of buspirone are headache, nausea,
dizziness, and sometimes feelings of restlessness. Buspirone has no
sedative or hypnotic effects.
Special points The short half-life (2 to 11 hours) necessitates dosing three times daily.
Atypical neuroleptics
Olanzapine
In an open-label study, 11 HD patients were treated with olanzapine for
several indications, including disruptive behavior and “psychomotor
agitation” [11, Class IV]. After 6 and 12 months, the behavioral score of
the Unified Huntington’s Disease Rating Scale (UHDRS) [18] was sig-
nificantly reduced, whereas the UHDRS motor score was unchanged.
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study with 10 patients, with significant changes in behavior, including ir-
ritability [8, Class IV]. Reported dosages of olanzapine as a treatment for
agitationvarybetween5mgand10mgdailyincombinationwithvalproate
[9, Class IV]. Impulsivity and aggressive behavior diminished with 5 mg of
olanzapine. Chorea movements and functioning in activities of daily life
improved when the dose was increased to 10 mg per day [10, Class IV].
Contraindications Risk for narrow-angle glaucoma.
Main drug interactions Concentrations of olanzapine are increased by coadministration of the
CYP1A2 inhibitor fluvoxamine and decreased by coadministration of the
CYP1A2 inducer carbamazepine.
Main side effects Somnolence, orthostatic hypotension, hyperglycemia, dry mouth, constipa-
tion, dyspepsia, increased appetite, prolonged QT interval, and tremor are
associated with olanzapine use. Olanzapine is more likely than the other
neuroleptics to cause weight gain.
Special points The dopamine D2 antagonist properties of olanzapine may explain its pos-
sible benefits in the improvement of chorea.
Risperidone
In a patient with anger, anxiety, and impulsive behavior, risperidone was
initiated after a treatment with haloperidol. The dosage was titrated
gradually up to 1 mg twice daily, giving a moderate improvement in
movement and overall psychiatric symptoms [19, Class IV]. Another case
report described a late-onset HD patient who showed behavioral changes
with temper outbursts and psychotic symptoms, which disappeared after
starting risperidone at a dosage of 1 mg twice daily [20, Class IV]. A
retrospective review of a group of HD patients treated with risperidone
(average dose, 2.5 mg) for an average of 15 months showed improved
psychiatric functioning measured with the UHDRS behavioral score, but
the effect on irritability was not specified [21￿, Class III].
Contraindications No strict contraindications.
Main drug interactions Concurrent use of risperidone and phenytoin or SSRIs may produce extra-
pyramidal symptoms [14]. Carbamazepine has been shown to decrease the
plasma concentration of risperidone. Otherwise, risperidone has little effect
on other drugs.
Main side effects The most frequent adverse effects observed with risperidone are insomnia,
agitation, anxiety, headache, weight gain, nausea and vomiting, and extra-
pyramidal effects. Less frequent effects are prolonged QT interval, postural
hypotension, dizziness, fatigue, sexual dysfunction, and hyperglycemia.
Quetiapine
With dosages varying from 150 mg to 300 mg daily, improvement of
behavioral symptoms, including irritability, was noted in five HD
patients without worsening of motor functioning [22, Class IV]. How-
ever, all patients had multiple psychiatric symptoms and were treated
with several types of medications. In a case report concerning an elderly
HD patient with hypersexuality, the addition of quetiapine (25 mg at
bedtime) to cyproterone for his deviant sexual behavior was effective in
reducing agitation [23, Class IV].
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Main drug interactions Coadministration of the CYP3A4 inducers carbamazepine and phenytoin
increases theclearanceof quetiapine.Inhibitors of CYP3A4, suchascimetidine,
ketoconazole, and protease inhibitors, reduce quetiapine clearance [14].
Main side effects The most common adverse effects of quetiapine are somnolence, headache,
orthostatic hypotension, and dizziness, which are usually transient. Quetia-
pine is also associated with weight gain, constipation, increase of heart rate,
prolonged QT interval, and rise in liver transaminases.
Aripiprazole
In a patient with irritability and delusions, aripiprazole (20 mg per day)
gave an improvement of his psychotic symptoms and his personal hy-
giene, though the effect on irritability remained unclear [24, Class IV].
One advanced symptomatic patient with agitation showed an improve-
ment of agitation with aripiprazole (15 mg per day), with good control
of motor symptoms and without adverse effects [25, Class IV]. However,
precise assessment of behavioral functioning in this patient was not
possible because of severe cognitive dysfunction.
Contraindications No strict contraindications.
Main drug interactions Coadministration of the CYP3A4 inducers carbamazepine and phenytoin
increasestheclearanceofaripiprazole.InhibitorsofCYP3A4,suchascimetidine,
ketoconazole, and protease inhibitors, reduce aripiprazole clearance. CYP2D6
inhibitors (eg, quinidine) increase aripiprazole plasma concentrations [14].
Main side effects Orthostatic hypotension, nausea, and vomiting are the most frequent adverse
effects.Aripiprazolerarelyinducesextrapyramidalandmetabolicadverseeffects.
Mood stabilizers
Valproate
One study reported an effective treatment of agitation with valproate,
1500 mg daily, with a plasma concentration range from 60 to 80 μg/mL,
in combination with olanzapine [19, Class IV].
Contraindications Preexisting hepatic or renal failure, hepatitis, pancreatitis, bone marrow de-
pression, and hematologic coagulation disorders are contraindications.
Main drug interactions Coadministration with lithium may result in a drug-induced tremor. Val-
proate also interacts with carbamazepine. Valproate decreases the clearance
of amitriptyline and nortriptyline [14].
Main side effects Nausea, vomiting, dyspepsia, and diarrhea are the most common adverse
effects in the first month of treatment. Other possible effects are sedation,
ataxia, dysarthria, tremor, hair loss, and weight gain.
Carbamazepine
Carbamazepine (500 mg/d) was effectively used in combination with
haloperidol, clonazepam, and a strict behavior modification plan in a
patient with aggressive and disinhibited behavior [26, Class IV].
Contraindications Atrioventricular block, a history of bone marrow depression, acute por-
phyria, and hepatic or renal failure are relative contraindications.
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many drugs. For the most part, adding carbamazepine lowers the plasma
concentration of affected drugs, including oral contraceptives and warfarin.
Carbamazepine may increase plasma concentrations of clomipramine and
phenytoin. Carbamazepine should not be used in combination with
monoamine oxidase inhibitors.
Main side effects Adverse effects particularly occur in the initial stages of therapy. These effects
include drowsiness, sedation, headache, ataxia, nystagmus, diplopia, cardiac
conduction disorder, dermatologic problems, and hepatitis. Blood dyscrasia
is a severe, but rare adverse effect of carbamazepine.
Lamotrigine
Only one study describes an effective treatment with lamotrigine
(300 mg/d), together with clonazepam (4 mg/d) in a patient with irri-
tability, mood swings, and depression [27, Class IV].
Contraindications No strict contraindications.
Main drug interactions The lamotrigine concentration is increased with concurrent administration of
valproate, and to a lesser extent with sertraline. Lamotrigine plasma con-
centrations are decreased with concomitant administration of carbamaze-
pine, phenytoin, or phenobarbital [14].
Main side effects Common adverse effects are dizziness, ataxia, somnolence, headache, di-
plopia, blurred vision, nausea, vomiting, and dermatologic side effects. These
dermatologic problems vary from self-limiting skin rashes to severe Stevens-
Johnson syndrome.
Lithium carbonate
In a small, double-blind, crossover trial with six female patients, a
combination of lithium and haloperidol during 3 weeks resulted in a
decrease of irritability and angry outbursts, but this effect did not occur
when either drug was administered separately [12, Class III].
Contraindications Renal failure, cardiac conduction disorder, and Addison’s disease are con-
traindications. Lithium should be used with caution in patients with diabetes
mellitus and hypothyroidism.
Main drug interactions Coadministration of lithium with anticonvulsants or antipsychotics may
increase lithium concentrations and aggravate adverse effects. Most diuretics
decrease renal lithium clearance and increase lithium concentrations. Non-
steroidal anti-inflammatory drugs can decrease lithium clearance, thereby
increasing lithium concentrations. Combining lithium with methyldopa,
verapamil, or diltiazem may cause neurotoxicity [14].
Main side effects The most common adverse effects of lithium are increased thirst, polyuria, ede-
ma, tremor, thyroid dysfunction, weight gain, fatigue, diarrhea, nausea, vomit-
ing, cardiac effects, dermatologic problems, and mild cognitive impairment.
Acetylcholinesterase inhibitors
Donepezil
No clinical or statistical improvement in behavioral, cognitive, or func-
tional assessment was measured in an open-label study with 10 mg per
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However, a high dropout rate of 50% was noted after 6 weeks of treatment.
Contraindications No strict contraindications.
Main drug interactions Metabolism of donepezil may be increased by phenytoin, carbamazepine,
rifampicin, or phenobarbital.
Main side effects Nausea, diarrhea, anxiety, sedation, fatigue, vomiting, and weight loss due to
anorexia are possible adverse effects of donepezil. Donepezil has been re-
lated to bradyarrhythmias.
Special points Donepezil may have a positive effect on memory and concentration
impairments.
Rivastigmine
Data on the effect of rivastigmine (3 mg twice daily) show a tendency to
improvementofthetotalscoreoftheUHDRSbehavioralscale[29,ClassIV].
Contraindications Severe hepatic failure.
Main drug interactions Rivastigmine has no significant known drug interactions.
Main side effects The most common adverse effects are nausea, vomiting, dizziness, headache,
diarrhea, fatigue, somnolence, and anorexia.
Special points Rivastigmine may have a positive effect on memory and concentration
impairments.
Beta-adrenergic receptor antagonists (beta-blockers)
Propranolol
With dosage varying from 30 to 240 mg daily, propranolol was an effective
treatmentforaggressioninthreepatients[30,ClassIV],butpropranololalso
precipitated paradoxic aggression in a patient with HD [31,C l a s sI V ] .
Contraindications Beta-adrenergic receptor antagonists are contraindicated in people with
asthma, insulin-dependent diabetes, congestive heart failure, significant
vascular disease, atrioventricular conduction defect, persistent angina, or
hypothyroidism.
Main drug interactions Concomitant administration of propranolol results in increased plasma
concentrations of antipsychotics, anticonvulsants, theophylline, and levo-
thyroxine [14].
Main side effects Hypotension and bradycardia are adverse effects of beta-blockers.
Special points The dosage of beta-blockers must be individually titrated, with regular
measurement of pulse and blood pressure.
Cannabinoids
Nabilone
One HD patient had an improvement of mood, was calmer and more
relaxed after she started smoking of cannabis [32, Class IV]. Nabilone, a
synthetic 9-keto cannabinoid, was given in a larger study, resulting in an
430 Psychiatric Manifestations of Neurologic Diseaseoverall improvement of UHDRS behavioral and the Neuropsychiatric
Inventory scores [13￿, Class III].
Contraindications Allergy to cannabinoids, history of psychosis, and liver dysfunction are
contraindications for the use of nabilone.
Main drug interactions Concomitant use of benzodiazepines may potentiate the central nervous
system effects of nabilone.
Main side effects Sedation, drowsiness, dizziness, forgetfulness, headache, mood changes,
hallucinations, dry mouth, blurred vision, and loss of appetite are possible
adverse effects of nabilone.
Special points Nabilone is available in a few countries and is indicated for treatment of
nausea and vomiting associated with cancer. Theoretically, nabilone has a
high potential for abuse.
Other interventions
Behavioral therapy
Both classical and operant conditioning are useful in managing
irritability. Operant conditioning involves the reinforcement of more
appropriate behaviors and discouragement of inappropriate behav-
iors [33]. Furthermore, limits and consequences of deviant behavior
need to be clearly defined to the patient [34]. Especially for patients
in an advanced disease stage, a behavior modification plan may in-
clude a structured daily schedule and reinforcement of desired
behaviors [26].
Nursing interventions
Stressful psychosocial factors may result in irritability. After identification
of stressors, the patient should be helped to look for ways to avoid these
stressors and to develop concrete ways of coping, in order to decrease the
level of stress within the nursing home or day care setting. Patients may
be advised to break tasks down into simpler components.
Adaptive devices and specialized equipment are valuable in main-
taining comfort, thereby decreasing the expression of problematic
behaviors [33].
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